A groundbreaking clinical trial reveals that low-dose radiation therapy may provide significant pain relief for individuals suffering from knee osteoarthritis, offering a safer alternative to traditional pain management methods.
Are you feeling a dip in mood and energy as autumn arrives? Discover how light therapy can help combat seasonal depression and improve your well-being this winter. Learn expert tips on using light boxes effectively.
This week in science news, a breakthrough gene therapy shows promise in treating Huntington's disease, while a Vancouver man regains his sight through a revolutionary tooth-in-eye surgery. Additionally, Super Typhoon Ragasa wreaks havoc across Asia, and new studies reveal shocking links between pollution and health.
Scientists have engineered a modified strain of Salmonella to combat cancer, showing promise in colorectal cancer treatment in mice. This innovative approach could revolutionize cancer therapies.
A groundbreaking gene therapy has shown it can slow the progression of Huntington's disease by 75% in a small clinical trial. This one-time treatment could reshape the future for patients with this rare brain disorder.
Scientists from University College London have made a groundbreaking discovery that could slow the progression of Huntington’s disease. A new gene therapy, AMT-130, shows promising results in clinical trials, potentially changing lives forever.
In a groundbreaking announcement, gene therapy company uniQure revealed an experimental treatment that has slowed the progression of Huntington's disease. Although still in early testing, this could signal new hope for patients battling this devastating condition.
The Trump administration has sparked debate by proposing restrictions on one medication linked to autism, while advocating for broader access to another under investigation. What does this mean for future healthcare decisions?
In a remarkable turn of events, 8-year-old Nathaniel Schumann, who was nonverbal, began to speak in full sentences just two weeks after starting a clinical trial for an autism treatment. This development raises hopes for many families.
Merck's new injectable cancer drug, Keytruda Qlex, promises to transform patient treatment with a quick administration time and flexible dosing, all while maintaining effectiveness. Available in late September, this shift is critical as the market braces for biosimilar competition.
